Bone marrow transplantation in the Wiskott-Aldrich syndrome. Complete hematological and immunological reconstitution

Transplantation. 1982 Nov;34(5):284-8. doi: 10.1097/00007890-198211000-00009.

Abstract

A 21-month-old boy with the Wiskott-Aldrich syndrome conditioned with cyclophosphamide and dimethyl myleran received bone marrow from an HLA-matched sibling. Complete hematological chimerism was achieved. During the first 3 months after transplantation, in vitro B cell function, measured by a direct plaque assay, was abnormal, T cell helper activity impaired, and suppressor T cell function was excessive. These abnormalities resolved gradually over 16 months. Antibody responses to the T-dependent antigen, bacteriophage phi X174, were initially low, then became normal; antibody responses to keyhole limpet hemocyanin (KLH) and to 4 of 12 type-specific pneumococcal polysaccharide antigens were adequate when studied 9 months after transplantation. The clinical response was excellent: the patient has been free of infection, no longer has a bleeding tendency, and has shown normal growth and development.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Antibody Formation
  • Bacterial Vaccines / therapeutic use
  • Blood Transfusion
  • Bone Marrow Transplantation*
  • Female
  • Humans
  • Immunity, Cellular
  • Infant
  • Lymphocyte Activation
  • Male
  • Methotrexate / therapeutic use
  • Platelet Transfusion
  • Pneumococcal Vaccines
  • Wiskott-Aldrich Syndrome / blood
  • Wiskott-Aldrich Syndrome / immunology
  • Wiskott-Aldrich Syndrome / therapy*

Substances

  • Bacterial Vaccines
  • Pneumococcal Vaccines
  • Methotrexate